Vesugen in vasculogenic erectile dysfunction and lower-limb arterial disease
Comparison in people · 2014
- What was studied
- 41 men with atherosclerosis, lower-limb ischemia and vascular erectile dysfunction. Vesugen 26, untreated comparison 15. Recruitment January 2009 to July 2010.
- Main finding
- At one month, peak systolic velocity in the dorsal penile artery was about 26.3 vs 16.3 cm/s with Vesugen versus untreated comparison. Figure values are approximate.
Reported findings and study design
26 received Vesugen for one month and 15 had no specific treatment. Assessments used penile artery Doppler and a modified quality-of-life questionnaire.
Population or model 41 men with atherosclerosis, lower-limb ischemia and vascular erectile dysfunction. Vesugen 26, untreated comparison 15. Recruitment January 2009 to July 2010.
Dose, route and schedule
Vesugen monotherapy at 200 µg/day for one month. The paper does not specify the dosage form or route. Controls received no specific treatment during observation.
Protocol source ↗ · Original Russian journal PDF, methods and Figures 1–3
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dorsal penile artery peak systolic velocity | ≈26.3 vs 16.3 cm/s | At month 1. Approximate baseline values 15.4 and 15.6 cm/s. · Figure 2 marks p < 0.004 against controls. |
| Deep dorsal penile artery peak systolic velocity | ≈25.1 vs 16.4 cm/s | At month 1. Approximate baseline values 15.7 and 16.2 cm/s. · Figure 3 marks p < 0.001 against controls. |
| Sexual function questionnaire | Reported improvement versus unchanged control | Modified SF-36 with sexual-function questions. A standard IIEF-5 effect estimate is unavailable. |
The Doppler estimates come from the plotted bars. The article text uses cm/s even though the figure axes print m/s. Allocation, masking and harms remain unclear.
Source for these results ↗ · Reviewed 2026-11-13
Study limitations and source details
Study limitations
- Allocation and masking are undocumented. The figures print m/s, while the methods and results interpret the scale as cm/s. Figures report no dispersion.
- A 2013 paper from the same team also describes 41 patients. Participant overlap remains unresolved. The reports cannot support 82 unique participants.
Source details
Journal publication
Original Russian journal PDF, methods and Figures 1–3
Sources checked
Citation
Kitachev KV, Sazonov AB, Kozlov KL, Petrov KIu, Sliusarev AS, Khavinson VKh. Vesugen in vasculogenic erectile dysfunction and lower-limb arterial disease Advances in gerontology = Uspekhi gerontologii 27(1):156-159. PMID 25051774